Editas Medicine Eyes Mid-2026 IND Filing After EDIT-401 Cuts LDL-C by 90%
Editas Medicine’s lead candidate EDIT-401 achieved over 90% LDL-C reduction in preclinical studies and is on track for IND/CTA submission by mid-2026 with first-in-human HeFH trials planned later this year and proof-of-concept data due year-end. It held $146.6m cash, funding operations into Q3 2027 while reducing its 2025 net loss to $160.1m.
1. EDIT-401 Preclinical Efficacy and IND/CTA Plans
Editas Medicine’s in vivo candidate EDIT-401 demonstrated over 90% mean LDL-C reduction in non-human primates and will present additional preclinical data by mid-2026. The company remains on track to submit an IND/CTA application for EDIT-401 by mid-2026 to support first-in-human dosing in HeFH patients.
2. First-in-Human Trial Timeline
The company plans to initiate its first-in-human HeFH trial later this year, targeting early human proof-of-concept data by the end of 2026. Enrollment of the dose-finding portion is expected to conclude with topline data available in 2027.
3. Cash Position and Runway
Editas ended 2025 with $146.6 million in cash and cash equivalents, sufficient to fund operations and planned development activities into the third quarter of 2027. This strong cash position supports the advancement of EDIT-401 toward regulatory and clinical milestones without near-term financing needs.
4. 2025 Financial Performance
Full-year 2025 net loss narrowed to $160.1 million from $237.1 million in 2024, reflecting reduced clinical and manufacturing costs following the reni-cel program discontinuation. Collaboration revenues rose to $40.5 million, while R&D and G&A expenses fell by $109.2 million and $22.1 million respectively.